Two experts lead a discussion about chronic lymphocytic leukemia (CLL), focusing on updates in management and special considerations when treating with BTK inhibitors.
EP. 1: Chronic Lymphocytic Leukemia and BTK Inhibitors
Amy Goodrich, RN, MSN, CRNP, and Kirollos S. Hanna, PharmD, BCPS, BCOP, provide an overview of chronic lymphocytic leukemia (CLL) and the role BTK inhibitors play in treatment.
EP. 2: Selecting Treatment for CLL and Managing BTK Inhibitor-Associated Toxicities
Two experts discuss their approach to selecting therapy for patients with CLL and provide insight on managing adverse events when using BTK inhibitors.
EP. 3: Q and A Session
Amy Goodrich, RN, MSN, CRNP, and Kirollos S. Hanna, PharmD, BCPS, BCOP, answer audience questions regarding CLL and BTK inhibitors during a question & answer session.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.